Last reviewed · How we verify
docetaxel and carboplatin
Docetaxel is a microtubule inhibitor that disrupts cell division, while carboplatin is a platinum-based alkylating agent that cross-links DNA, both leading to cell death.
Docetaxel is a microtubule inhibitor that disrupts cell division, while carboplatin is a platinum-based alkylating agent that cross-links DNA, both leading to cell death. Used for Non-small cell lung cancer, breast cancer, ovarian cancer, and other solid tumors, Prostate cancer.
At a glance
| Generic name | docetaxel and carboplatin |
|---|---|
| Sponsor | Sanofi |
| Drug class | Taxane and platinum-based chemotherapy |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Docetaxel works by binding to tubulin and preventing the formation of microtubules, which are essential for cell division. This leads to cell cycle arrest and apoptosis. Carboplatin, on the other hand, forms platinum-DNA adducts that interfere with DNA replication and transcription, ultimately causing cell death.
Approved indications
- Non-small cell lung cancer, breast cancer, ovarian cancer, and other solid tumors
- Prostate cancer
Common side effects
- Neutropenia
- Anemia
- Thrombocytopenia
- Fatigue
- Nausea and vomiting
Key clinical trials
- HER2 Directed Dendritic Cell Vaccine During Neoadjuvant Therapy of HER2+Breast Cancer (EARLY_PHASE1)
- Platinum and Taxane Chemo in Met Castration Resistant Prostate Cancer Patients With Alterations in DNA Damage Response Genes (PHASE3)
- A Clinical Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer (PHASE3)
- Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers (PHASE2, PHASE3)
- A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan Versus Standard of Care in the Treatment of Advanced Urothelial Cancer (PHASE3)
- Chemotherapy Before Surgery and Radiation Therapy or Surgery and Radiation Therapy Alone in Treating Patients With Nasal and Paranasal Sinus Cancer That Can Be Removed by Surgery (PHASE2)
- Immunotherapy With Chemotherapy and Chemoradiation for Advanced Squamous Cancer of Nasal Cavity / Paranasal Sinuses (I-NAPA) (PHASE2)
- A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- docetaxel and carboplatin CI brief — competitive landscape report
- docetaxel and carboplatin updates RSS · CI watch RSS
- Sanofi portfolio CI